Comment
doi: 10.1007/s00415-018-8772-4.
Repurposed drugs for use in Parkinson's disease
Affiliations
- PMID: 29423610
- DOI: 10.1007/s00415-018-8772-4
Item in Clipboard
Comment
Repurposed drugs for use in Parkinson's disease
J Neurol.
2018 Mar.
No abstract available
Comment on
-
Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Neurol. 2016 Mar;15(3):249-58. doi: 10.1016/S1474-4422(15)00389-0. Epub 2016 Jan 13. Lancet Neurol. 2016. PMID: 26795874 Clinical Trial.
-
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.Lancet. 2017 Oct 7;390(10103):1664-1675. doi: 10.1016/S0140-6736(17)31585-4. Epub 2017 Aug 3. Lancet. 2017. PMID: 28781108 Free PMC article. Clinical Trial.
-
A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.Mov Disord. 2018 Feb;33(2):329-332. doi: 10.1002/mds.27259. Epub 2017 Dec 26. Mov Disord. 2018. PMID: 29278279 Free PMC article. Clinical Trial.
Similar articles
-
The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.BMC Neurol. 2013 Dec 3;13:188. doi: 10.1186/1471-2377-13-188. BMC Neurol. 2013. PMID: 24299497 Free PMC article. Clinical Trial.
-
Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Neurol. 2016 Mar;15(3):249-58. doi: 10.1016/S1474-4422(15)00389-0. Epub 2016 Jan 13. Lancet Neurol. 2016. PMID: 26795874 Clinical Trial.
-
Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease.BMC Neurol. 2021 Oct 29;21(1):422. doi: 10.1186/s12883-021-02430-2. BMC Neurol. 2021. PMID: 34715821 Free PMC article. Clinical Trial.
-
Rivastigmine: in Parkinson's disease dementia.CNS Drugs. 2006;20(9):739-47; discussion 748-50. doi: 10.2165/00023210-200620090-00003. CNS Drugs. 2006. PMID: 16953649 Review.
-
Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.Drugs Today (Barc). 2007 Jun;43(6):349-59. doi: 10.1358/dot.2007.43.6.1107987. Drugs Today (Barc). 2007. PMID: 17612707 Review.
Cited by
-
Drug reprofiling history and potential therapies against Parkinson's disease.Front Pharmacol. 2022 Oct 26;13:1028356. doi: 10.3389/fphar.2022.1028356. eCollection 2022. Front Pharmacol. 2022. PMID: 36386233 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
